SCHEMBL20140075

SCHEMBL20140075

Cc1cccc(OCc2ccccc2)c1I

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.67
MAPK1 P28482 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
HTR1A P08908 3/20 0.55
ADRA1D P25100 2/20 0.55
ADRA1A P35348 2/20 0.55
ADRA1B P35368 2/20 0.55
RXRA P19793 1/20 0.53
RXRB P28702 1/20 0.53
RXRG P48443 1/20 0.53
LIPE Q05469 1/20 0.51
APP P05067 4/20 0.50
SGMS2 Q8NHU3 2/20 0.49
MAPK14 Q16539 2/20 0.49
DRD2 P14416 1/20 0.49
PTGER1 P34995 1/20 0.47
LTA4H P09960 1/20 0.46
EDNRA P25101 1/20 0.46
HTR6 P50406 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2896277 0.88 MAPT (0.64) MAPTMAPK1TDP1L3MBTL1HTR1A
SCHEMBL265584 0.84 MAPK1 (0.70) MAPTMAPK1TDP1L3MBTL1HTR1A
SCHEMBL29874217 0.84 MAPK1 (0.70) MAPTMAPK1TDP1L3MBTL1HTR1A
SCHEMBL2880443 0.83 MAPT (0.81) MAPTMAPK1TDP1L3MBTL1HTR1A
SCHEMBL19612388 0.81 L3MBTL1 (0.67) MAPTMAPK1TDP1L3MBTL1HTR1A
SCHEMBL26132599 0.81 MAPT (0.51) MAPTMAPK1TDP1L3MBTL1HTR1A
SCHEMBL19612191 0.80 MAPT (1.00) MAPTMAPK1TDP1L3MBTL1HTR1A
SCHEMBL23883421 0.80 MAPT (0.55) MAPTMAPK1TDP1L3MBTL1HTR1A
SCHEMBL8497192 0.80 MAPT (0.65) MAPTMAPK1TDP1L3MBTL1HTR1A
SCHEMBL23294813 0.80 APP (0.62) MAPTMAPK1TDP1L3MBTL1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10815210-B2 Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators JANSSEN PHARMACEUTICA NV (BE) 2020-10-27 US disclosed
WO-2018089449-A1 BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815210-B2 Benzocyclobutane derivatives useful as dual SGLT1 / SGLT2 modulators SLC5A2, SLC5A1, SLC2A2 MAPT 1495/4885MAPK1 1584/4885TDP1 4340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.